Companion diagnostic
TcLand Expression offers Pharma/Biotech partners its expertise in the development of Companion Diagnostics, based on its Gene Expression Biomarkers platform. As for TcLand Expression‘s proprietary biomarkers, partnered Companion Diagnostics will be developed according to our integrated approach.
TcLand Expression is proficient in the development of Companion Diagnostics for obtaining regulatory approval at the same time as receiving approval for the associated treatment.
Companion Diagnostics and Biomarkers provide significant value for the companion drug, and notably by :
- Reducing the time, cost, and failure rate of clinical trials
- Reviving drugs that failed clinical trials or were withdrawn from the market
- Avoiding withdrawal of marketed drugs
- Anticipating regulatory mandates that could disrupt development budgets and market plans;
- Improving competitive profile of the drug;
- Changing paradigm for marketing and sales of pharmaceutical products, including management of the product lifecycle
Companion Diagnostics’ implementation
Source : PMC
Based on TcLand Expression’s Gene Expression Biomarkers platform, Companion Diagnostic programs are implemented at any time of the development process of a drug, from the preclinical phase through to phase III.